{"slideshow_credits": null, "snippet": "Actavis is not alone in its penchant for acquisitions, Robert Cyran writes for Reuters Breakingviews. Valeant Pharmaceuticals and Endo Health Solutions are among those that have also enhanced their market values by snatching up rivals, slashing costs...", "abstract": "Actavis is not alone in its penchant for acquisitions, Robert Cyran writes for Reuters Breakingviews. Valeant Pharmaceuticals and Endo Health Solutions are among those that have also enhanced their market values by snatching up rivals, slashing costs and minimizing taxes.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Robert", "role": "reported", "lastname": "CYRAN", "rank": 1, "organization": ""}], "original": "By ROBERT CYRAN"}, "web_url": "http://dealbook.nytimes.com/2014/02/18/actavis-deal-may-become-the-standard-for-drug-deals/", "lead_paragraph": null, "headline": {"main": "Actavis Deal May Become the Standard for Drug Deals", "kicker": "DealBook"}, "_id": "5303b83338f0d835dccb32ee", "word_count": "382", "multimedia": [{"height": 126, "url": "images/2014/02/19/business/dbpix-breakingviews-drug/dbpix-breakingviews-drug-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/02/19/business/dbpix-breakingviews-drug/dbpix-breakingviews-drug-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 569, "url": "images/2014/02/19/business/dbpix-breakingviews-drug/dbpix-breakingviews-drug-articleLarge.jpg", "legacy": {"xlarge": "images/2014/02/19/business/dbpix-breakingviews-drug/dbpix-breakingviews-drug-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "569"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/02/19/business/dbpix-breakingviews-drug/dbpix-breakingviews-drug-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/02/19/business/dbpix-breakingviews-drug/dbpix-breakingviews-drug-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-02-18T14:41:38Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "persons", "value": "Icahn, Carl C", "rank": "1"}, {"name": "organizations", "value": "Warner Chilcott Ltd", "rank": "5"}, {"name": "organizations", "value": "Watson Pharmaceuticals Inc", "rank": "6"}, {"name": "organizations", "value": "Endo Pharmaceuticals Holdings Inc", "rank": "2"}, {"name": "organizations", "value": "Forest Laboratories Inc", "rank": "3"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "rank": "4"}, {"name": "organizations", "value": "Actavis Group", "rank": "1"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "1"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}